JP6204921B2 - シクロスポリンａの形態２およびその作製方法 - Google Patents

シクロスポリンａの形態２およびその作製方法 Download PDF

Info

Publication number
JP6204921B2
JP6204921B2 JP2014542396A JP2014542396A JP6204921B2 JP 6204921 B2 JP6204921 B2 JP 6204921B2 JP 2014542396 A JP2014542396 A JP 2014542396A JP 2014542396 A JP2014542396 A JP 2014542396A JP 6204921 B2 JP6204921 B2 JP 6204921B2
Authority
JP
Japan
Prior art keywords
hours
suspension
temperature
cyclosporin
heating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014542396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014533300A (ja
Inventor
ウー・コー
スコット・ダブリュー・スミス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2014533300A publication Critical patent/JP2014533300A/ja
Application granted granted Critical
Publication of JP6204921B2 publication Critical patent/JP6204921B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/306—Extraction; Separation; Purification by precipitation by crystallization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2014542396A 2011-11-15 2012-11-14 シクロスポリンａの形態２およびその作製方法 Expired - Fee Related JP6204921B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161559830P 2011-11-15 2011-11-15
US61/559,830 2011-11-15
PCT/US2012/064985 WO2013074608A1 (en) 2011-11-15 2012-11-14 Cyclosporine a form 2 and method of making same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017168227A Division JP6513755B2 (ja) 2011-11-15 2017-09-01 シクロスポリンａの形態２およびその作製方法

Publications (2)

Publication Number Publication Date
JP2014533300A JP2014533300A (ja) 2014-12-11
JP6204921B2 true JP6204921B2 (ja) 2017-09-27

Family

ID=47222337

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014542396A Expired - Fee Related JP6204921B2 (ja) 2011-11-15 2012-11-14 シクロスポリンａの形態２およびその作製方法
JP2017168227A Active JP6513755B2 (ja) 2011-11-15 2017-09-01 シクロスポリンａの形態２およびその作製方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017168227A Active JP6513755B2 (ja) 2011-11-15 2017-09-01 シクロスポリンａの形態２およびその作製方法

Country Status (11)

Country Link
US (4) US8796221B2 (enExample)
EP (2) EP3067363B1 (enExample)
JP (2) JP6204921B2 (enExample)
KR (1) KR102072252B1 (enExample)
CN (1) CN104039813B (enExample)
AU (3) AU2012339693B2 (enExample)
BR (1) BR112014011768A2 (enExample)
CA (1) CA2856034C (enExample)
ES (2) ES2578154T3 (enExample)
RU (1) RU2635547C2 (enExample)
WO (1) WO2013074608A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013074608A1 (en) * 2011-11-15 2013-05-23 Allergan, Inc. Cyclosporine a form 2 and method of making same
EP3263587A1 (en) 2012-06-01 2018-01-03 Allergan, Inc. Cyclosporin a analogs
CA2955037A1 (en) 2014-07-18 2016-01-21 Allergan, Inc. Suspension compositions of cyclosporin a for subconjunctival and periocular injection
TW201639873A (zh) 2015-01-08 2016-11-16 歐樂根公司 Ｍｅｂｍｔ側鏈已環化之環孢菌素衍生物
CN113117359B (zh) * 2021-03-05 2022-08-26 湘雅生物医药(湖州)有限公司 一种用于胶原蛋白提取用的无菌式蒸馏瓶
WO2024085235A1 (ja) 2022-10-20 2024-04-25 中外製薬株式会社 環状ペプチドの結晶の製造方法
KR20250160895A (ko) 2023-03-20 2025-11-14 추가이 세이야쿠 가부시키가이샤 고리형 펩타이드의 공결정을 제조하는 방법
CN116879437A (zh) * 2023-07-11 2023-10-13 苏州欧康维视生物科技有限公司 一种检测眼用植入剂的体外释放的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0391909B1 (en) 1987-09-03 1994-08-17 The University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
HU203564B (en) 1987-12-21 1991-08-28 Sandoz Ag Process for producing new orthorombos cyclosporin without solvatation
GB8916901D0 (en) * 1989-07-24 1989-09-06 Sandoz Ltd Improvements in or relating to organic compounds
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
US5382714A (en) * 1994-03-17 1995-01-17 The Catholic University Of America Process for isolation, purification, and recrystallization of lutein from saponified marigold oleoresin and uses thereof
PT789580E (pt) * 1994-11-03 2002-09-30 Novartis Ag Formulacoes de ciclosporina para administracao oral com composicao simples e alta biodisponibilidade e processo para a sua producao
TW581681B (en) * 1998-02-20 2004-04-01 Nektar Therapeutics Liquid crystal forms of cyclosporin
JP4208281B2 (ja) * 1998-02-26 2009-01-14 キヤノン株式会社 積層型光起電力素子
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
WO2005072701A1 (en) 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
JP6163482B2 (ja) 2011-05-27 2017-07-12 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ シクロスポリンａの結晶形態、その調製方法、およびその使用のための方法
WO2013074608A1 (en) * 2011-11-15 2013-05-23 Allergan, Inc. Cyclosporine a form 2 and method of making same

Also Published As

Publication number Publication date
EP3067363A1 (en) 2016-09-14
AU2012339693B2 (en) 2017-09-07
EP2780358B1 (en) 2016-03-23
AU2017272197A1 (en) 2018-01-04
US20180312543A1 (en) 2018-11-01
JP2017210488A (ja) 2017-11-30
US20160272681A1 (en) 2016-09-22
KR102072252B1 (ko) 2020-01-31
EP3067363B1 (en) 2018-01-17
ES2666191T3 (es) 2018-05-03
US9352014B2 (en) 2016-05-31
AU2019204591B2 (en) 2021-03-25
EP2780358A1 (en) 2014-09-24
CA2856034A1 (en) 2013-05-23
AU2012339693A1 (en) 2014-06-05
BR112014011768A2 (pt) 2017-05-09
CN104039813B (zh) 2017-08-29
RU2635547C2 (ru) 2017-11-14
CN104039813A (zh) 2014-09-10
AU2019204591A1 (en) 2019-07-18
WO2013074608A1 (en) 2013-05-23
US20130123193A1 (en) 2013-05-16
JP6513755B2 (ja) 2019-05-15
ES2578154T3 (es) 2016-07-21
RU2014123468A (ru) 2015-12-27
HK1202124A1 (zh) 2015-09-18
US10017541B2 (en) 2018-07-10
US20140303343A1 (en) 2014-10-09
CA2856034C (en) 2017-12-12
US8796221B2 (en) 2014-08-05
KR20140101790A (ko) 2014-08-20
JP2014533300A (ja) 2014-12-11

Similar Documents

Publication Publication Date Title
JP6204921B2 (ja) シクロスポリンａの形態２およびその作製方法
US10206971B2 (en) Suspensions of cyclosporin A form 2
TWI554522B (zh) 新穎環孢靈ａ晶形、其製備方法及其使用方法
HK1228924A (en) A process for crystallization of cyclosporin a form 2
HK1228924A1 (en) A process for crystallization of cyclosporin a form 2
HK1228924B (en) A process for crystallization of cyclosporin a form 2
HK1202124B (en) Cyclosporine a form 2 and method of making same

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20150410

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160912

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170313

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170901

R150 Certificate of patent or registration of utility model

Ref document number: 6204921

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees